Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 3, 2014, Pages 358-366

  Hussain, Mohammed Jubair ^a   Wilkinson, Alexander ^a   Bramwell, Vincent W ^a   Christensen, Dennis ^b   Perrie, Yvonne ^a  

^a ASTON UNIVERSITY   (United Kingdom)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

cationic liposomes; dimethyldioctadecylammonium; distearoyl sn glycero 3 phosphocholine; Th1 responses; vaccine adjuvant

Indexed keywords

CATIONIC LIPOSOMES; DIMETHYLDIOCTADECYLAMMONIUM; DISTEAROYL-SN-GLYCERO-3-PHOSPHOCHOLINE; TH1 RESPONSES; VACCINE ADJUVANT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; CATIONS; FEMALE; GLYCOLIPIDS; IMMUNITY, CELLULAR; LIPOSOMES; MICE; MICE, INBRED C57BL; PHOSPHATIDYLCHOLINES; QUATERNARY AMMONIUM COMPOUNDS; TH1 CELLS; VACCINES;

EID: 84894283400     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12173     Document Type: Article

References (26)

1. Cox JC, Coulter AR,. Adjuvants- a classification and review of their modes of action. Vaccine 1997; 15: 248-256.
2. Henriksen-Lacey M, et al. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J Control Release 2010; 142: 180-186.
3. Korsholm KS, et al. T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection. Immunology 2009; 129: 75-86.
4. Henriksen-Lacey M, et al. Comparison of the depot effect and immunogenicity of liposomes based on DDA, DC-Chol and DOTAP: prolonged liposome retention mediates stronger Th1 responses. Mol Pharm 2011; 8: 153-161.
5. Holten-Andersen L, et al. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 2004; 72: 1608-1617.
6. Davidsen J, et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 2005; 1718: 22-31.
7. Werninghaus K, et al. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9- dependent innate immune activation. J Exp Med 2009; 206: 89-97.
8. Henriksen-Lacey M, et al. Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and immunogenicity of the vaccine. J Control Release 2010; 145: 102-108.
9. Henriksen-Lacey M, et al. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. J Control Release 2011; 154: 131-137.
10. Senior J, Gregoriadis G,. Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. Life Sci 1982; 30: 2123-2136.
11. Aagaard C, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011; 17: 189-194.
12. Bangham AD, et al. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13: 238-252.
13. Christensen D, et al. Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying. Biochim Biophys Acta 2007; 1768: 2120-2129.
14. Ali S, et al. A differential scanning calorimetry study of phosphocholines mixed with paclitaxel and its bromoacylated taxanes. Biophys J 2000; 78: 246-256.
15. Agger EM, et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE 2008; 3: 1-10.
16. Christensen D, et al. CAF01 liposomes as a mucosal vaccine adjuvant: in vitro and in vivo investigations. Int J Pharm 2010; 390: 19-24.
17. Mazumdar T, et al. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine 2004; 22: 1162-1171.
18. McNeil SE, et al. Subunit vaccines: distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system. J Pharm Sci 2011; 100: 1856-1865.
19. Sable SB, et al. Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity. Clin Immunol 2007; 122: 239-251.
20. Vangala A, et al. Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J Control Release 2007; 119: 102-110.
21. Korsholm KS, et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 2007; 121: 216-226.
22. Christensen D, et al. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog. J Control Release 2012; 160: 468-476.
23. Perrie Y, et al. A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant. Hum Vaccin Immunother 2013; 12: 1374-1381.
24. Romero Mendez IZ, et al. Potentiation of the immune response to non-adsorbed antigens by aluminium-containing adjuvants. Vaccine 2007; 25: 825-833.
25. Hutchison S, et al. Antigen depot is not required for alum adjuvanticity. FASEB J 2012; 26: 1272-1279.
26. Kamath AT, et al. Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses. J Immunol 2012; 188: 4828-4837.